- Home
- RFAI vs URGN Comparison
RFAI vs URGN Comparison
Compare RFAI & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFAI
- URGN
- Stock Information
- Founded
- RFAI 2024
- URGN 2004
- Country
- RFAI Singapore
- URGN United States
- Employees
- RFAI N/A
- URGN N/A
- Industry
- RFAI
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- RFAI
- URGN Health Care
- Exchange
- RFAI NYSE
- URGN Nasdaq
- Market Cap
- RFAI 158.1M
- URGN 831.6M
- IPO Year
- RFAI 2024
- URGN 2017
- Fundamental
- Price
- RFAI $10.56
- URGN $19.22
- Analyst Decision
- RFAI
- URGN Strong Buy
- Analyst Count
- RFAI 0
- URGN 8
- Target Price
- RFAI N/A
- URGN $29.00
- AVG Volume (30 Days)
- RFAI 12.5K
- URGN 1.3M
- Earning Date
- RFAI 01-01-0001
- URGN 08-07-2025
- Dividend Yield
- RFAI N/A
- URGN N/A
- EPS Growth
- RFAI N/A
- URGN N/A
- EPS
- RFAI 0.33
- URGN N/A
- Revenue
- RFAI N/A
- URGN $91,871,000.00
- Revenue This Year
- RFAI N/A
- URGN $39.80
- Revenue Next Year
- RFAI N/A
- URGN $108.94
- P/E Ratio
- RFAI $32.44
- URGN N/A
- Revenue Growth
- RFAI N/A
- URGN 8.98
- 52 Week Low
- RFAI $10.06
- URGN $3.42
- 52 Week High
- RFAI $10.58
- URGN $19.69
- Technical
- Relative Strength Index (RSI)
- RFAI N/A
- URGN 76.29
- Support Level
- RFAI N/A
- URGN $18.37
- Resistance Level
- RFAI N/A
- URGN $19.36
- Average True Range (ATR)
- RFAI 0.00
- URGN 1.03
- MACD
- RFAI 0.00
- URGN 0.25
- Stochastic Oscillator
- RFAI 0.00
- URGN 91.26
About RFAI RF ACQUISITION CORP II
RF Acquisition Corp II is a blank check company.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.